Teva Pharmaceutical Finance Co., LLC, founded in 2011 and headquartered in New York, serves as a finance subsidiary for Teva Pharmaceutical Industries Ltd., a global leader in generic and specialty pharmaceuticals. The company primarily focuses on managing and financing the capital needs of its parent company through various financial instruments.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| TEVA 6.15% 2036-02-01 USDTeva Pharmaceutical Finance Co., LLC | United States | 2036-02-01 | 6.150 | 5.54 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Teva Pharmaceutical Finance Co. has been active in the bond market since its inception, with significant bond issuances aimed at supporting the financial framework of its parent company. Notably, in 2020, Teva issued a $2 billion senior unsecured note to help refinance existing debt, showcasing its commitment to maintaining liquidity and financial health. Current yields on Teva's bonds typically reflect the higher risk profile associated with the pharmaceutical sector, yet remain competitive within the industry. The bonds often feature attractive maturities, and recent news has highlighted ongoing efforts to improve credit metrics post-debt restructuring.